icon-folder.gif   Conference Reports for NATAP  
  EASL 47th Annual Meeting
April 18th - 22nd 2012
Barcelona, Spain
Back grey_arrow_rt.gif
Ribavirin Dose Modification in Treatment-naïve and Previously Treated Patients Who Received Telaprevir Combination Treatment: No Impact on Sustained Virologic Response in Phase 3 Studies
  Reported by Jules Levin
EASL 2012
M.S. Sulkowski1*, S. Roberts2, N.H. Afdhal3, P. Andreone4, M. Diago5, S. Pol6, F. Poordad7, S. Zeuzem8, L. Bengtsson9, D. Luo10, J. Witek10, N. Adda9
1. Johns Hopkins University School of Medicine, Baltimore, MD, USA, 2. Alfred Hospital, Melbourne, VIC, Australia, 3. Beth Israel Deaconess Medical Center, Boston, MA, USA, 4. Universita di Bologna, Bologna, Italy, 5. Hospital General de Valencia, Valencia, Spain, 6. Université Paris Descartes, Paris, France, 7. Cedars-Sinai Medical Center, Los Angeles, CA, USA, 8. Johann Wolfgang Goethe University, Frankfurt/Main, Germany, 9. Vertex Pharmaceuticals Incorporated, Cambridge, MA, 10. Janssen Research and Development, Titusville, NJ, USA.





Patient Disposition According to Ribavirin Dose Reductions
Figure 1: A) Ribavirin Dose Reductions in Treatment-naïve Patients From ADVANCE and ILLUMINATE During the Overall Treatment Phase B) Ribavirin Dose Reductions in Previously Treated Patients from REALIZE During the Overall Treatment Phase